Skip to main navigation

Top bar

Biogen.com Information Request Sign up for Alerts Search

Investor Relations

Overview

News

Events Presentations

SEC Filings Annual Reports

Stock Quote & Chart Analyst Coverage Investor FAQs

Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board

News

News

News Category

Year

January 14, 2008

FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease

January 10, 2008

Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors

January 8, 2008

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech

January 7, 2008

Biogen Idec Provides Business Update at Investor Meeting

January 7, 2008

Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis

January 3, 2008

Biogen Idec to Present at the 26th Annual JPMorgan Healthcare Conference

Pagination

First page
Previous page
…
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Current page 71

Displaying 701 - 706 of 706

Footer

Investors
Careers
Our Stories
Contact Us

Follow us

Bottom

Privacy Policy
Terms & Conditions
Forward-Looking Statements
Community Guidelines

Investor Relations

Overview

News

Events & Presentations

Events
Presentations

Financials

SEC Filings
Annual Reports

Stock Information

Stock Quote & Chart
Analyst Coverage
Investor FAQs

Corporate Governance

Governance Documents
Committee Composition & Charters
Leadership
Code of Business Conduct
Contact the Board

Top bar

Biogen.com

Information Request

Sign up for Alerts

Search

Follow us